AstraZeneca PLC Director/PDMR Shareholding (1296I)
31 March 2020 - 5:00PM
UK Regulatory
TIDMAZN
RNS Number : 1296I
AstraZeneca PLC
31 March 2020
31 March 2020 07:00 BST
Transactions by Persons Discharging Managerial
Responsibilities
Disclosure under Article 19 of the EU Market Abuse
Regulation
AstraZeneca PLC (the Company) announced that, on 27 March 2020,
awards of the Company's ordinary shares of $0.25 each (Ordinary
Shares) vested to certain Persons Discharging Managerial
Responsibilities of the Company (PDMRs) under the AstraZeneca
Performance Share Plan (AZPSP).
The AZPSP award was granted on 27 March 2015 and was subject to
a three-year performance period followed by a two-year holding
period before vesting. Application of the performance measures
specified at the time of grant resulted in 77% of the AZPSP award
vesting and the remaining unvested part lapsing.
Following the withholding of shares to satisfy certain tax
obligations arising on vesting, the PDMRs' beneficial interests in
Ordinary Shares changed as detailed in the table below:
PDMR Ordinary Shares
acquired under the
AZPSP
Pascal Soriot 74,698
--------------------
Marc Dunoyer 19,429
--------------------
For tax purposes, the fair market value of an Ordinary Share at
vest was 6882 pence, being the closing price on the last trading
day preceding the vesting.
Further details are set out in the attached notifications, made
in accordance with the requirements of the EU Market Abuse
Regulation.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Pascal Soriot
-------------------------- ------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------- ------------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name AstraZeneca PLC
-------------------------- ------------------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
-------------------------- ------------------------------------------------
4i Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
-------------------------- ------------------------------------------------
b) Nature of the transaction Acquisition of ordinary shares pursuant
to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration.
-------------------------- ------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0 74,698
----------
-------------------------- ------------------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
-------------------------- ------------------------------------------------
e) Date of the transaction 27 March 2020
-------------------------- ------------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Marc Dunoyer
-------------------------- ------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------- ------------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name AstraZeneca PLC
-------------------------- ------------------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
-------------------------- ------------------------------------------------
4i Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
-------------------------- ------------------------------------------------
b) Nature of the transaction Acquisition of ordinary shares pursuant
to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration.
-------------------------- ------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0 19,429
----------
-------------------------- ------------------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
-------------------------- ------------------------------------------------
e) Date of the transaction 27 March 2020
-------------------------- ------------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ------------------------------------------------
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide. Please visit astrazeneca.com and follow the Company on
Twitter @ AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHURSWRRWUOOAR
(END) Dow Jones Newswires
March 31, 2020 02:00 ET (06:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024